Gilead Sciences, Inc. (GILD) Stock

Healthcare · Drug Manufacturers - General · Member of S&P 500, NASDAQ 100

Gilead Sciences, Inc. (GILD) closed at USD 157.37 on 2026-10-15, a change of +36.1 % over the past year, with a market capitalization of USD 193.67B.

Gilead Sciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Gilead Sciences, Inc. key figures

Previous close

USD 157.37 (2026-10-15)

1-year change

+36.1 %

Market cap

USD 193.67B

Enterprise value

USD 214.95B

P/E ratio (trailing)

-58.94

P/E ratio (forward)

15.71

EPS (trailing)

-2.65

EPS (forward)

9.94

PEG ratio

2.34

Price to book

16.39

Revenue growth

10.2 %

Earnings growth

n/a

Dividend per share (trailing)

3.22

Short ratio

3.70

Employees

17,000

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Gilead Sciences, Inc. and compare it with other stocks.